



Uscom

ASX MEDIA RELEASE

Amended Appendix 3Y

Friday 27 August 2021

Attached is an amended appendix 3Y in relation to relevant interest in shares held by Robert Phillips.

On 2 July 2021, Uscom released an appendix 3Y disclosing the purchase by Mr Phillips of 125,000 shares. Inadvertently, contract notes for a further 40,579 shares purchased on 29 June 2021 were overlooked. Accordingly, the correct number of shares purchased by Mr Phillips disclosed in the Appendix 3Y should have been 165,579 shares.

On 5 July 2021, Uscom announced that 1,436,782 shares were issued to Mr Phillips pursuant to the Uscom Limited Equity Incentive Plan which had been approved at the Company's 2020 Annual General Meeting. On that date, an appendix 2A and a cleansing notice were released to the ASX in relation to the share issue. Due to an administrative oversight, the lodging of the necessary appendix 3Y in relation to the issue of shares was overlooked. An appendix 3Y disclosing the share issue has been released to the ASX today.

The Board of Uscom has reviewed the Company's Continuous Disclosure & External Communications Policy and its Corporate Governance Statement to ensure that all directors are aware of the internal procedures to ensure that the above omissions are not repeated.

About Uscom

Uscom Limited (UCM): An ASX listed innovative medical technology company specialising in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the **USCOM 1A** advanced haemodynamic monitor, Uscom **BP+** central blood pressure monitor, and the Uscom **SpiroSonic** digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks. **The USCOM 1A:** A simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The **USCOM 1A** device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.

The Uscom BP+: A supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterisation. The Uscom **BP+** replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom **BP+** provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension and pre-eclampsia, heart failure, intensive care, general practice and home care. The Uscom **BP+** is supported by the proprietary **BP+ Reporter**, an innovative stand alone software solution that provides a digital platform to archive patient



Uscom

ASX MEDIA RELEASE

examinations and images, trend measure progress over time, analyse pulse pressure waves and generate summary reports.

Uscom SpiroSonic digital multi-path ultrasonic spirometers: High fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. The **SpiroSonic** spirometers, **FLO**, **SMART**, and **AIR**, require no calibration, are durable, simple to disinfect, and are simple, inexpensive and accurate to use providing research quality pulmonary function testing in hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobileSpiroSonic APP and proprietary **SpiroSonic** software, **SpiroReporter**, with wireless interfacing to provide remote tele-monitoring of pulmonary disease. The devices are specialised for assessment of asthma, COPD, sleep disordered breathing, industrial lung disease and COVID monitoring for pulmonary fibrosis.

VENTITEST: Digital ultrasonic ventilator calibration solution is a new system for calibrating ventilators. All ventilators and respiratory support devices require calibration to maintain the accuracy with which they measure the pressure, flow and volume of air they deliver. **VENTITEST** and **VENTITEST-S**, based on advanced SpiroSonic technology provides a calibration solution that provides for simple and accurate calibration, archiving, analysis and reporting and optimal ventilation performance.

For more information, please visit: www.uscom.com.au

Authorised by:

Rob Phillips
Executive Chairman
rob@uscom.com.au

Brett Crowley
Company Secretary

This announcement is approved for release to the ASX by the Board of Uscom Limited.

Amended Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Uscom Limited
ABN	35 091 028 090

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Robert Allan Phillips
Date of last notice	29 June 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	29 June 2021
No. of securities held prior to change	30,600,174
Class	Ordinary shares
Number acquired	165,579
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$27,446

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change	30,765,753 fully paid ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market purchase

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
---	----

⁺ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Uscom Limited
ABN	35 091 028 090

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Robert Allan Phillips
Date of last notice	27 August 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	5 July 2021
No. of securities held prior to change	30,765,753
Class	Ordinary shares
Number acquired	1,436,782
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change	32,202,535 fully paid ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issued pursuant to the Uscom Limited Equity Incentive Plan

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
---	----

⁺ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.